Literature DB >> 16011037

Trimodal GSTT1 and GSTM1 genotyping assay by real-time PCR.

I Girault1, R Lidereau, I Bièche.   

Abstract

The GSTT1 and GSTM1 genes are characterized by the existence of a GST*0 null allele responsible for a lack of enzyme activity, with the respective null genotypes GSTT1*0/0 and GSTM1*0/0. The three resulting genotypes (GSTs*1/1, *1/0 and *0/0) are associated with a trimodal distribution of glutathione-conjugator activity. Previous epidemiological studies have only evaluated the cancer risk associated with the GST null genotype relative to the two GST carrier genotypes (GSTs1*1/1 and *1/0). We developed GSTT1 and GSTM1 TaqMan real-time quantitative PCR assays to discriminate each of the three genotypes, with the albumin gene (ALB) as reference. The mean N(GSTT1*1/1) value was 1.0 (95% confidence interval 0.80-1.20). The mean N(GSTT1*1/0) value was 0.48 (95% CI 0.36-0.60). One (3.4%) of the 29 DNA samples yielded the GSTM1*1/1 genotype (N(GSTM1*1/1) = 1), a frequency in keeping with the Hardy-Weinberg distribution. The mean N(GSTM1*1/0) value was 0.50 (95% CI 0.42-0.58). All GSTT1*0/0 and GSTM1*0/0 samples yielded N(GST) values of 0 (Ct = 40); the frequencies of these genotypes (27.6% and 55.2%, respectively) were in keeping with published data. The GSTT1 and GSTM1 real-time PCR assays described here unambiguously discriminate each of the three existing genotypes which should be valuable for assessing the relative risk of cancer associated with each of the three GST genotypes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16011037

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  8 in total

1.  Prognosis of hormone-dependent breast cancer seems to be influenced by KEAP1, NRF2 and GSTM1 genetic polymorphisms.

Authors:  Micaela Almeida; Mafalda Soares; Ana Cristina Ramalhinho; José Fonseca Moutinho; Luiza Breitenfeld
Journal:  Mol Biol Rep       Date:  2019-04-02       Impact factor: 2.316

2.  GSTM1 and GSTT1 copy numbers and mRNA expression in lung cancer.

Authors:  Melissa Rotunno; Tram K Lam; Aurelie Vogt; Pier Alberto Bertazzi; Jay H Lubin; Neil E Caporaso; Maria Teresa Landi
Journal:  Mol Carcinog       Date:  2012-03-05       Impact factor: 4.784

3.  Simultaneous genotyping of GSTT1 and GSTM1 null polymorphisms by melting curve analysis in presence of SYBR Green I.

Authors:  Fátima Marín; Nadia García; Xavier Muñoz; Gabriel Capellà; Carlos A González; Antonio Agudo; Núria Sala
Journal:  J Mol Diagn       Date:  2010-03-04       Impact factor: 5.568

4.  Loss of GSTM1, a NRF2 target, is associated with accelerated progression of hypertensive kidney disease in the African American Study of Kidney Disease (AASK).

Authors:  Jamison Chang; Jennie Z Ma; Qing Zeng; Sylvia Cechova; Adam Gantz; Caroline Nievergelt; Daniel O'Connor; Michael Lipkowitz; Thu H Le
Journal:  Am J Physiol Renal Physiol       Date:  2012-12-05

5.  Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology.

Authors:  P David Josephy
Journal:  Hum Genomics Proteomics       Date:  2010-06-13

6.  Copy number variants of GSTM1 and GSTT1 in relation to lung cancer risk in a prospective cohort study.

Authors:  Tram Kim Lam; Ingo Ruczinski; Kathy Helzlsouer; Yin Yao Shugart; Kelly E Li; Sandra Clipp; Paul T Strickland; Anthony J Alberg
Journal:  Ann Epidemiol       Date:  2009-04-25       Impact factor: 3.797

7.  Multiplex PCR detection of GSTM1, GSTT1, and GSTP1 gene variants: simultaneously detecting GSTM1 and GSTT1 gene copy number and the allelic status of the GSTP1 Ile105Val genetic variant.

Authors:  Anders Buchard; Juan J Sanchez; Kim Dalhoff; Niels Morling
Journal:  J Mol Diagn       Date:  2007-10-04       Impact factor: 5.568

8.  Combined Effects of GSTM1 Null Allele and APOL1 Renal Risk Alleles in CKD Progression in the African American Study of Kidney Disease and Hypertension Trial.

Authors:  Gabor Bodonyi-Kovacs; Jennie Z Ma; Jamison Chang; Michael S Lipkowitz; Jeffrey B Kopp; Cheryl Ann Winkler; Thu H Le
Journal:  J Am Soc Nephrol       Date:  2016-03-03       Impact factor: 10.121

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.